cromolyn sodium, intranasal (OTC)

Brand and Other Names:NasalCrom
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

intranasal spray

  • 5.2mg/spray

Allergic Rhinitis

1 spray each nostril q6-8hr, may increase to 6 times/day; may take 2-4 weeks before symptomatic relief observed

For best results, initiate 1-2 weeks before contact with allergens

Dosage Forms & Strengths

intranasal spray

  • 5.2mg/spray

Allergic Rhinitis

<2 years: Safety and efficacy not established

≥2 years: 1 spray each nostril q6-8hr, may increase to 6 times/day; may take 2-4 weeks before symptomatic relief observed

For best results, initiate 1-2 weeks before contact with allergens

Next:

Adverse Effects

Frequency Not Defined

Transient nasal stinging or sneezing after administration

Headache

Unpleasant taste

Hoarseness (cough)

Epistaxis

Previous
Next:

Warnings

Contraindications

Hypersensitivity

Cautions

No benefit in acute setting

Symptoms may reoccur while tapering the dose

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: C

Lactation: Unknown whether distributed in breast milk, caution advised

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Mast cell stabilizer

Pharmacokinetics

Onset of action: 1-2 weeks

Half-life elimination: 80-90 min

Excretion: Urine and feces

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.